Literature DB >> 9406996

Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines.

M Hallek1, C Neumann, M Schäffer, S Danhauser-Riedl, N von Bubnoff, G de Vos, B J Druker, K Yasukawa, J D Griffin, B Emmerich.   

Abstract

Binding of interleukin-6 to its receptor (IL-6R) induces the association of the IL-6R alpha chain (IL-6Ralpha) with a 130-kDa transmembrane glycoprotein, gp130. This event activates tyrosine kinases of the Janus kinase (JAK) family and transduces signals to the cytosol or nucleus. To further characterize the biochemical mechanisms by which IL-6 promotes cell proliferation, we investigated the effects of IL-6 on the growth and transmembrane signaling of several lymphoid cell lines. In the IL-6-dependent cell line B-9, IL-6 induced a rapid, transient, and concentration-dependent tyrosine phosphorylation of several cytosolic proteins as detected by antiphosphotyrosine immunoblots. The molecular weight of major bands on sodium dodecyl sulfate-polyacrylamide gel electrophoresis was 44, 65, 70, 80, 137, 148, 184, and 190 kDa, respectively. Similar effects of IL-6 on tyrosine phosphorylation were observed in the human multiple myeloma cell line LP-1. Because JAKs were unlikely to mediate all the biological effects of IL-6, we investigated whether members of the Src family of tyrosine kinases were also activated in B-9 or LP-1 cells. IL-6 induced the activation and tyrosine phosphorylation of p59Fyn, p56/59Hck, and p56Lyn. Coprecipitation experiments with anti-Hck, anti-Lyn, anti-Fyn, and anti-gp130 antibodies revealed a physical association with gp130 of p56/59Hck and p56Lyn, but not p59Fyn, in LP-1 cells. Together, these results show for the first time that several Src kinases may become activated by IL-6 (p59Fyn, p56/59Hck, and p56Lyn) and associate with gp130 (p56/59Hck and p56Lyn).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9406996

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  23 in total

Review 1.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

2.  Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases.

Authors:  M Schaeffer; M Schneiderbauer; S Weidler; R Tavares; M Warmuth; G de Vos; M Hallek
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

3.  Logic programming reveals alteration of key transcription factors in multiple myeloma.

Authors:  Bertrand Miannay; Stéphane Minvielle; Olivier Roux; Pierre Drouin; Hervé Avet-Loiseau; Catherine Guérin-Charbonnel; Wilfried Gouraud; Michel Attal; Thierry Facon; Nikhil C Munshi; Philippe Moreau; Loïc Campion; Florence Magrangeas; Carito Guziolowski
Journal:  Sci Rep       Date:  2017-08-23       Impact factor: 4.379

4.  Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.

Authors:  Pilar de la Puente; Feda Azab; Barbara Muz; Micah Luderer; Jack Arbiser; Abdel Kareem Azab
Journal:  Leuk Lymphoma       Date:  2015-11-16

5.  Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth.

Authors:  Serk In Park; Changki Lee; W David Sadler; Amy J Koh; Jacqueline Jones; Jung Won Seo; Fabiana N Soki; Sun Wook Cho; Stephanie D Daignault; Laurie K McCauley
Journal:  Cancer Res       Date:  2013-09-26       Impact factor: 12.701

6.  Inhibition of the SRC Kinase HCK Impairs STAT3-Dependent Gastric Tumor Growth in Mice.

Authors:  Ashleigh R Poh; Amy R Dwyer; Moritz F Eissmann; Ashwini L Chand; David Baloyan; Louis Boon; Michael W Murrey; Lachlan Whitehead; Megan O'Brien; Clifford A Lowell; Tracy L Putoczki; Fiona J Pixley; Robert J J O'Donoghue; Matthias Ernst
Journal:  Cancer Immunol Res       Date:  2020-01-28       Impact factor: 11.151

7.  Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.

Authors:  Yun Dai; Shuang Chen; Rena Shah; Xin-Yan Pei; Li Wang; Jorge A Almenara; Lora B Kramer; Paul Dent; Steven Grant
Journal:  Blood       Date:  2010-12-10       Impact factor: 22.113

8.  HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and mediates the effects of IL-6 on cell migration.

Authors:  Xiaoqing Lu; Jun Chen; Raquel Malumbres; Elena Cubedo Gil; David M Helfman; Izidore S Lossos
Journal:  Blood       Date:  2007-09-06       Impact factor: 22.113

9.  The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells.

Authors:  Qun Zhou; Yuan Yao; Solveig G Ericson
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

10.  Identification of STOML2 as a putative novel asthma risk gene associated with IL6R.

Authors:  J A Revez; M C Matheson; J Hui; S Baltic; A James; J W Upham; S Dharmage; P J Thompson; N G Martin; J L Hopper; M A R Ferreira
Journal:  Allergy       Date:  2016-03-24       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.